Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Clindamycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Tract Infections 1 Urinary Bladder Neoplasms 1 Surgical Wound Infection 1 Skin Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Inflammation 1 Infections 1 Head and Neck Neoplasms 1 Exanthema 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Carboplatin 339 Cisplatin 238 Paclitaxel 203 Radiotherapy 193 Pemetrexed 187 Docetaxel 169 Gemcitabine 156 pembrolizumab 140 Erlotinib Hydrochloride 107 Etoposide 98 Bevacizumab 91 Magnetic Resonance Spectroscopy 90 Specimen Handling 73 Radiosurgery 71 Nivolumab 71 durvalumab 68 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 48 Irinotecan 42 atezolizumab 41 Topotecan 39 Radiation 39 Biopsy 39 Cyclophosphamide 38 Standard of Care 37 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡